| Quarter | Call date | Disclosure | Financial quality | Kept | Missed | |
|---|---|---|---|---|---|---|
| Q2'26 | July 30, 2026 | 8/12 | 2 high, 5 medium, 2 low flags | 2 | 0 | Call sheet → |
| Q1'26 | April 30, 2026 | 12/12 | 1 medium, 5 low flags | 4 | 0 | Call sheet → |
| Q4'25 | February 5, 2026 | 12/12 | 2 medium, 6 low flags | 5 | 0 | Call sheet → |
| Marked | Status | Promise |
|---|---|---|
| Q2'26 | Delivered | Continue investments in specialty businesses 22% growth in specialty & care earnings demonstrates investment payoff |
| Q2'26 | Pending | Debt-to-cap closer to 40% target by year-end Currently at 42.8%, slight deterioration from Q1 |
| Q2'26 | Pending | Expect cash flow to be back half-weighted Q2 cash flow 'in line' but no specific number given |
| Q2'26 | Pending | Cigna Healthcare fully insured plans adopt Signature in 2027 Confirmed as next step in rollout |
| Q2'26 | Pending | Signature model broader market launch in 2028 Reiterated timeline, still on track |
| Q2'26 | Exceeded | Raise full year 2026 adjusted EPS outlook to at least $30.35 Raised further to $30.45 in Q2 |
| Q1'26 | Delivered | Maintain strong capital discipline Debt-to-cap improved 70bps to 42.3%, raised EPS guidance |
| Q1'26 | Delivered | Improve prior authorization process 15% reduction in prior auth volume, removed hundreds of procedures |
| Q1'26 | Exceeded | Disciplined portfolio shaping to focus on core growth platforms Two major portfolio actions this quarter - more aggressive than expected |
| Q1'26 | Delivered | Drive affordability through biosimilar adoption HUMIRA penetration now 'vast majority of eligible scripts,' STELARA ramping |
| Q1'26 | Pending | At least $6.9B Evernorth earnings for 2026 Reaffirmed guidance despite Q1 PBS headwinds |
| Q1'26 | Pending | Transform pharmacy benefits model with rebate-free approach by 2028 On track - now calling it 'standard offering' and providing 50% adoption target |
| Q4'25 | Exceeded | Standard rebate-free offering starting January 2028 (Q3) Accelerated Cigna Healthcare adoption to 1/1/2027, added 50% EverNorth target by 2028 |
| Q4'25 | Delivered | Investment spending over 'next 2 years' for PBM transformation (Q3) Refined to 'largely dissipate after 2027' - more specific timeline provided |
| Q4'25 | Pending | Stop-loss margin expansion in 2026 (Q3) Tracking 'in line with expectations' for 2-year recovery plan through 2027 |
| Q4'25 | Delivered | Approximately 97% retention in PBM business (Q3) 'Over 97%' achieved as selling season concluded |
| Q4'25 | Exceeded | Specialty & Care growth toward high end of 8-12% algorithm (Q3) Q4 delivered 14% revenue growth, maintained high-end guidance for 2026 |
| Q4'25 | Delivered | EPS growth in 2026 despite PBM headwinds (Q3) Delivered with 'at least $30.25' guidance representing 1.4% minimum growth |
Get free previews of our earnings-call research: the key changes, management scores, and questions worth investigating. Subscribe for full call sheets and deeper analysis.
Subscriptions are managed by Substack. If the form does not load, subscribe directly. Or follow the RSS feed.